Express News | Arbutus to Report Third Quarter 2024 Financial Results and Provide Corporate Update
Arbutus Biopharma Highlights Imdusiran's Potential in Hepatitis B
Arbutus Announces Multiple Abstracts Highlighting Imdusiran Data Accepted for Presentation at AASLD - The Liver Meeting 2024
Arbutus Biopharma CSO Michael Sofia Announces Retirement Plans
JMP Securities Maintains Arbutus Biopharma(ABUS.US) With Buy Rating, Maintains Target Price $5
Q3 Pharma and Biotech Layoffs in Charts: More Than 1000 Each in July and August